Jan de Kerpel is a recognized biotech/healthcare business and finance expert with more than 20 years of experience in the fields of drug development, equity analysis and capital market growth financing. He currently serves as Managing Director Corporate Finance Life Science/Healthcare at Kempen & Co. Prior to Kempen & Co, he was during one decade Senior Equity Analyst, Pharma & Biotech at KBC Securities, which earned him 3 times the Financial Times/Starmine “Best European Biotech analyst” award. He started his professional activities in drug development at Tibotec-Virco (now JNJ) and Devgen (now Syngenta).

Jan has a proven track record in successfully identifying investment opportunities to a continuously expanding international investor base and has been instrumental in raising €10 billion in IPOs and other equity financing for numerous European biotech, medtech, health services and pharmaceutical companies. Jan serves as advisor to sector and government bodies and is an invited speaker on topics relating healthcare innovation, strategic development and financing. 

Academically, Jan earned a master and PhD in life sciences (Univ Leuven), postgraduate in Business Administration (Univ Leuven) and an executive MBA (Vlerick Business School), complemented with corporate finance classes (Univ Brussels).